Chengqi Yi
@YiChengqi
Followers
278
Following
57
Media
1
Statuses
30
Professor at Peking University. Yi lab is interested in RNA modifications, Epitranscriptomics and Genome Editing. Welcome to communicate with us!
Peking Uni, Beijing, China
Joined April 2021
RT @NatureBiotech: AlphaFold2 and RoseTTAFold are limited to predicting the 3D structure of proteins. A new all-atom method models complete….
science.org
Deep-learning methods have revolutionized protein structure prediction and design but are presently limited to protein-only systems. We describe RoseTTAFold All-Atom (RFAA), which combines a residu...
0
228
0
RT @Xuemei_RNAlab: A cool technology developed by my colleague Chengqi Yi at Peking University to correct premature termination codon mutat….
0
11
0
Our updated RESTART v3 for premature termination codons rescue @NatureBiotech, which boasts editing efficiency and accuracy. Based on Dr. @Jinghui Song's outstanding work!.
nature.com
Nature Biotechnology - Disease-related premature stop codons are efficiently corrected by harnessing near-cognate tRNAs.
1
12
71
RT @NatureBiotech: Near-cognate tRNAs increase the efficiency and precision of pseudouridine-mediated readthrough of premature termination….
0
32
0
RT @Jinghui_Song: Honored that our RNA base editor "RESTART" has been selected as the best technology of Molecular Cell 2023. Huge thanks t….
0
1
0
SIMPLE-seq @NatureBiotech developed by Dr. Dongsheng Bai @bds1993 et al. that simultaneously detects 5mC and 5hmC at the single-cell and single-molecule level!.Jointly published by Prof. Chenxu Zhu @chenxuzhu from Cornell University and us.
0
14
75
#RESTART #RNAEditing .We are delighted that RESTART has been recommended as one of the "Best of Cell Press" and published in @MolecularCell . This is a novel and elegant RNA editing tool developed by Dr. @Jinghui_Song et al. Link to our paper: .
0
0
3
We have witnessed this moment!!!.
The first approved CRISPR medicine in the world for sickle cell disease and beta thalassemia!. A huge victory for biotechnology, patients, and humanity.
0
0
1
RT @pdhsu: The first approved CRISPR medicine in the world for sickle cell disease and beta thalassemia!. A huge victory for biotechnology,….
businesswire.com
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the United Kingdom (U.K.) Medicines and Health...
0
137
0
RT @NatRevMCB: 🚨 New #NRMCBReview Alert! 🚨. "Regulation and functions of non-m6A mRNA modifications" by Hanxiao Sun, Kai Li, Cong Liu and @….
0
4
0
RT @WolfPrize_: Congratulations to Chuan He, 2023 Wolf Prize laureate in Chemistry!.@UChiChemistry @UChicago
0
103
0
RT @JRNLclub: Always double check your work. @HermanZhaoZzzz. discusses extensive off-target editing in the nuclear genome induced by a mit….
jrnlclub.org
Huannan Zhao explains mitochondrial base editor induces substantial nuclear off-target mutations
0
2
0
RT @JRNLclub: Always double check your work. @HermanZhaoZzzz discusses extensive off-target editing in the nuclear genome induced by a mito….
0
2
0
We are pleased to introduce our new idea of RNA base editing, a safe RNA base editing tool. Excellent work by Dr. Jinghui Song @Jinghui_Song and Liting Dong!. Click to view the full article.↓.
So excited to share our work (. We developed a programmable RNA base editor, termed RESTART in the lab of Prof. Yi (@YiChengqi). Hoping our work will be a promising tool for therapeutics of PTC-disease.
0
1
3
Congratulations to our "GLORI" team!.
Absolute quantification of single-base m⁶A methylation in the mammalian transcriptome using GLORI - @PKU1898
0
2
14
RT @NatureBiotech: Absolute quantification of single-base m⁶A methylation in the mammalian transcriptome using GLORI - @PKU1898
https://t.c….
0
16
0
RT @BoXia7: I’m super excited to start my new journey as @GRO_Broad Fellow @broadinstitute and a Junior Fellow of the Society of Fellows @H….
0
8
0
We are looking for postdoctoral fellows and welcome friends from all over the world to contact us. Our official website is
0
2
5